$OCGN OCU400 broad RP analysis, realistic revenue projections, and a bonus market cap/share price timeline. Most won’t realize how conservative this framework actually is. 🍻
@POTUS@realDonaldTrump
https://t.co/uPgvueHf4Y
How about those energy bills cut in half within the first 12 months, 😆😆😆😆
What a joke you are. Lured people in with that one just like no tax on OT. Fraud!!!
@NattaCop Considering Shankar was with Pfizer when it was at its all time high, I’m hoping that he does the same for OCGN. Another 5 year wait is nothing when you’ve been accumulating the last 5. 🤑
Millions of patients with GA could see a potential new standard of care with OCU410, a one shot for life therapy. 46% reduction in lesion growth at just 12 months, versus existing approaches which generate ~22% reduction at 24 months and require 6-12 injections a year besides potential for other AEs. Stay tuned for full phase 2 data in March!
To further expedite product development, the FDA announced a more flexible approach to the agency’s oversight of chemistry, manufacturing and control requirements for cell and gene therapies. https://t.co/Pix3Qfq4zj